Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01062451 · ClinicalTrials.gov registry record · Phase 1
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
A Phase 1 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT01062451 is a Phase 1 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 80 participants.
The verdict
NCT01062451, a Phase 1 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The primary objective is to determine the dose dependent effects of treatment with perindopril on methamphetamine (MA)-induced craving and on the reinforcing effects of MA indexed by MA self-administration. We will also determine the effects of treatment with candesartan on MA-induced craving and on the reinforcing effects of MA indexed by MA self-administration.
Interventions
- DRUG Placebo
- DRUG Candesartan
- DRUG Perindopril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-11-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01062451
The ClinicalTrials.gov registry entry for NCT01062451 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01062451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01062451 about?
NCT01062451 is a clinical study titled "An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence". The primary objective is to determine the dose dependent effects of treatment with perindopril on methamphetamine (MA)-induced craving and on the reinforcing effects of MA indexed by MA self-administration. We will also determine the effects of treatment with candesartan on MA-induced craving and on...
What is the current status of trial NCT01062451?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2009-05. Estimated completion is 2013-11-20.
What interventions are being tested in trial NCT01062451?
The interventions under investigation include: Placebo (DRUG), Candesartan (DRUG), Perindopril (DRUG).
Who is sponsoring clinical trial NCT01062451?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.